BridgeBio Pharma (BBIO) Gross Profit (2020 - 2026)

BridgeBio Pharma has disclosed Gross Profit across 7 years of filings, most recently posting $184.6 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $184.6 million, up 61.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $551.7 million (up 354.09% YoY), and the FY2025 annual result was $481.1 million, up 120.67% from the prior year.
• Gross Profit came in at $184.6 million for Q1 2026 at BridgeBio Pharma, up from $146.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $210.5 million in Q1 2024 to a low of -$401000.0 in Q3 2022.
• The 5-year median for Gross Profit is $3.6 million (2023), against an average of $60.3 million.
• Across the five-year window, Gross Profit tumbled 145.06% in 2022 and soared 17816.77% in 2024, its largest moves.
• BridgeBio Pharma's Gross Profit stood at $1.2 million in 2022, then fell by 6.21% to $1.1 million in 2023, then jumped by 231.12% to $3.8 million in 2024, then surged by 3746.0% to $146.1 million in 2025, then advanced by 26.36% to $184.6 million in 2026.
• The last three Gross Profit figures came in at $184.6 million (Q1 2026), $146.1 million (Q4 2025), and $114.1 million (Q3 2025), per Business Quant data.